

Form 605Corporations Act 2001
Section 671B**Notice of ceasing to be a substantial holder**To Company Name/Scheme Creso Pharma LimitedACN/ARSN 609 406 911**1. Details of substantial holder (1)**Name Suburban Holding Pty Ltd <Suburban Super Fund A/C>ACN/ARSN (if applicable) 106 824 471The holder ceased to be a substantial holder on 31/03/2017The previous notice was given to the company on 24/10/2016The previous notice was dated 24/10/2016**2. Changes in relevant interests**

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's votes affected
31/03/2017	Suburban Holding Pty Ltd <Suburban Super Fund A/C>	Dilution due to Placement	n/a	6,500,000 ordinary shares	6,500,000
27/03/2017 to 31/03/2017	Suburban Holding Pty Ltd <Suburban Super Fund A/C>	See Annexure A	See Annexure A	See Annexure A	See Annexure A

3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
n/a	

4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
Suburban Holding Pty Ltd <Suburban Super Fund A/C>	Level 53, 19 Martin Place, Sydney NSW 2000

Signature

print name



capacity Director

sign here



date 31/03/2017

DIRECTIONS

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
- (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:
 - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
 - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.
- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (6) The voting shares of a company constitute one class unless divided into separate classes.
- (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

ASIC Form 605

Creso Pharma Limited – ACN 106 824 471

Annexure “A”

Changes in Relevant Interests

Date of Change	Nature of Change	Consideration	Class and number of securities	Persons votes affected
31/03/2017	Off market transfer	\$0.75 per share	528,589	528,589
27/03/2017	On market sale	\$0.814 per share	499,039	499,039
28/03/2017	On market sale	\$0.787 per share	500,961	500,961
29/03/2017	On market sale	\$0.809 per share	455,402	455,402
30/03/2017	On market sale	\$0.790 per share	324,646	324,646
31/03/2017	On market sale	\$0.776 per share	145,284	145,284